Technology
Health
Biotechnology

ChemoCentryx

$7.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.08 (-1.13%) As of 2:28 PM EDT today
-$0.08 (-1.13%) Today

Why Robinhood?

You can buy or sell ChemoCentryx and other stocks, options, ETFs, and crypto commission-free!

About CCXI

ChemoCentryx, Inc. Common Stock, also called ChemoCentryx, is a biopharmaceutical company engages in the development and commercialization of medicines. Read More It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.

Employees
76
Headquarters
Mountain View, California
Founded
1996
Market Cap
412.99M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
581.76K
High Today
$7.25
Low Today
$6.86
Open Price
$7.11
Volume
119.81K
52 Week High
$14.98
52 Week Low
$6.16

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

CCXI News

ReutersAug 6

Edited Transcript of CCXI earnings conference call or presentation 5-Aug-19 9:00pm GMT

10

CCXI Earnings

-$0.27
$0.09
$0.44
$0.80
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 7, After Hours

More CCXI News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.